Your Article Summary
See Latest ArticlesSanofi-aventis and Biotechnology company
Exelixis enter into an Exclusive Global Alliance
for Novel Targeted Oncology Therapies
Sanofi-aventis, 05/29/09
Sanofi-aventis and Exelixis, Inc. announced a global license agreement for XL147 and XL765 and an exclusive collaboration for the discovery of inhibitors of phosphoinositide-3 kinase for the management of solid malignancies. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation and cell survival, as well as resistance to chemotherapy and radiotherapy.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
What Makes a Generic Medication Generic?
Journal of Psychosocial Nursing and Mental Health Services, 12/18/09
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
CCHIT Appoints Officers
HealthDataManagement, 12/18/09